Clinical Trials - January 9, 2026
Sobi to advance Gamifant in interferon-gamma-driven sepsis
Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.
In a new job - January 8, 2026
Q-linea announces changes in US commercial leadership
Q-linea has announces that Jim Kathrein will step down as VP US Commercial Operations.
Business - January 8, 2026
A treatment shift? 4 x Nordic progress beyond GLP-1
In the wake of the groundbreaking GLP-1 receptor agonists, a number of new obesity treatments and weight management approaches are emerging – and a few of them come from the Nordic region.
Clinical Trials - January 8, 2026
Herantis Pharma reports encouraging data from Phase 1b trial
Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease, states the company.
Clinical Trials - January 7, 2026
BioInvent reports promising Phase 2a study data
BioInvent International has announced encouraging interim results from its ongoing Phase 2a signal-seeking study evaluating BI-1808, a novel immuno-oncology candidate, in combination with MSD’s anti-PD-1 therapy KEYTRUDA in patients with recurrent ovarian cancer who have progressed following platinum-based therapy.
Science News - January 7, 2026
New study: Home blood tests – new possibilities for Alzheimer’s research
Scientists in Sweden, the US and several other European countries have carried out the first large-scale validation of an easily accessible test method that is independent of geographical proximity to specialized healthcare infrastructure.
